Loading clinical trials...
Loading clinical trials...
NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations: Conceptual Model Assessments (CMA) Sub-study
Conditions
Interventions
Buprenorphine Injection
Buprenorphine Sublingual Product
Locations
12
United States
Gateway Community Services
Jacksonville, Florida, United States
Massachusetts General Hospital HOPE Clinic
Boston, Massachusetts, United States
Boston Medical Center
Boston, Massachusetts, United States
University of New Mexico Milagro Clinic
Albuquerque, New Mexico, United States
University of Cincinnati Health Perinatal Addictions Program
Cincinnati, Ohio, United States
CODA, Inc.
Portland, Oregon, United States
Start Date
July 21, 2020
Primary Completion Date
November 6, 2024
Completion Date
November 6, 2024
Last Updated
March 16, 2026
NCT03745339
NCT06965530
NCT05336188
NCT06284278
NCT05942313
NCT06273683
Lead Sponsor
T. John Winhusen, PhD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions